Retatrutide vs MOTS-c
Retatrutide and MOTS-c come from opposite ends of metabolic research — one a triple hormone-receptor agonist engineered by Eli Lilly's incretin program, the other a signaling peptide discovered hiding inside mitochondrial DNA — but both show up in conversations about how metabolism can be modulated at a molecular level.
At a Glance
| Retatrutide | MOTS-c | |
|---|---|---|
| Category | Weight Loss / Metabolic | Longevity & Cellular Health |
| Molecular class | Long-acting, unimolecular triple-receptor agonist peptide | 16-amino-acid mitochondrial-derived peptide (MDP) |
| Discovery | Coskun et al., Cell Metabolism, 2022 (Eli Lilly) | 2015, Changhan David Lee (USC), Cell Metabolism |
| Primary mechanism | Simultaneous GIP, GLP-1, and glucagon receptor agonism | AMPK activation; mitochondria-to-nucleus signaling |
| Primary research focus | Energy expenditure, glycemic control, body composition | Mitochondrial signaling, metabolic regulation, exercise physiology |
| Human trial data | Phase 2 complete; TRIUMPH-1, -2, -3 (Phase 3) complete or reported | None for MOTS-c itself; Phase 2a (MOTS-MET) underway |
| Regulatory status | Investigational; BLA submission planned Q1 2027 | Investigational; no regulatory filing |
| Sold by KYIN | Yes — see product page | Yes — see product page |
How They Differ
Retatrutide came out of Eli Lilly's incretin-biology research group — the same program behind tirzepatide. Where earlier compounds in that line activated one or two hormone receptors, Lilly's researchers engineered Retatrutide as a single molecule that activates three at once: GIP, GLP-1, and glucagon. Adding glucagon receptor activity on top of the two incretin pathways was a deliberate design choice intended to layer glucagon's own energy-expenditure and hepatic lipid-oxidation effects on top of the appetite and glycemic benefits the other two receptors provide. See its full discovery history.
MOTS-c comes from an entirely different research tradition. It's a functional signaling peptide encoded not in nuclear DNA but inside mitochondrial DNA itself, within a short open reading frame in the 12S rRNA gene — a discovery that effectively opened up a new research category, now called mitochondrial-derived peptides (MDPs). Rather than acting on a cell-surface hormone receptor, MOTS-c is studied for its ability to activate AMPK and signal from the mitochondrion back to the nucleus, influencing metabolism and cellular stress response from the inside out. See its full discovery history.
Clinical Trial Data
Retatrutide: A Phase 2 trial (New England Journal of Medicine, 2023) reported up to 24.2% mean weight loss at 48 weeks. The Phase 3 TRIUMPH-1 trial (2,339 adults) reported 28.3% mean weight loss at the 12mg dose over 80 weeks, with 45.3% of participants losing at least 30% of body weight. TRIUMPH-2 (published in The Lancet) found 20.8% mean weight loss and up to 1.6% A1C reduction in adults with type 2 diabetes, and TRIUMPH-3 reported 22.6% mean weight loss in adults with cardiovascular disease, though its full results are not yet peer-reviewed. Retatrutide remains investigational and has not received regulatory approval anywhere; Eli Lilly has stated it plans to submit a Biologics License Application to the FDA in Q1 2027.
MOTS-c: MOTS-c itself has not completed a human clinical trial. CB4211, a related but distinct analog developed by CohBar, was tested in a Phase 1a/1b trial in 20 adults with obesity and elevated liver fat, meeting its safety endpoint and reducing liver enzymes ALT (-25%) and AST (-17%) relative to placebo. A Phase 2a trial of MOTS-c itself (MOTS-MET, NCT07505745) is currently underway in 120 adults with prediabetes; results have not yet been posted.
Why They're Sometimes Discussed Together
Retatrutide and MOTS-c aren't studied as a combination the way compounds in KYIN's blends are — they sit in different catalogue categories and work through unrelated mechanisms. The comparison comes up because both are reference points in metabolic-regulation research: Retatrutide represents the receptor-agonism approach to weight and glycemic control that has produced the most advanced human trial data of any compound in KYIN's catalogue, while MOTS-c represents an earlier-stage, mechanistically distinct approach centered on mitochondrial signaling rather than hormone receptors. Researchers interested in energy expenditure and metabolic regulation from multiple angles often end up reading both literatures.
Retatrutide vs MOTS-c questions
Why are Retatrutide and MOTS-c compared when they're in different categories?
Retatrutide sits in KYIN's Weight Loss / Metabolic category and MOTS-c in Longevity & Cellular Health, but their research literatures overlap at metabolic regulation: Retatrutide works through triple hormone-receptor agonism (GIP/GLP-1/glucagon) while MOTS-c works through mitochondrial AMPK signaling, making them two very different entry points into the same broader question of how metabolism can be modulated.
Which has more human clinical trial data, Retatrutide or MOTS-c?
Retatrutide, by a wide margin. It has completed Phase 2 and three Phase 3 trials (TRIUMPH-1 through TRIUMPH-3) involving thousands of participants, with a BLA submission planned for Q1 2027. MOTS-c itself has not completed any human trial — a Phase 2a trial (MOTS-MET, NCT07505745) is currently underway in 120 adults with prediabetes, and the only completed human data involves CB4211, a distinct analog developed by a different company.
Does this comparison mean Retatrutide and MOTS-c are approved for a particular use?
No. Retatrutide remains investigational and has not received regulatory approval anywhere. MOTS-c has not completed human trials. This page compares both for educational and research context only; KYIN Peptides sells both strictly for laboratory research use, not for human or animal use.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.